Document is current
Any future updates will be listed below
-
Authors
Mason, Mike
Lapuente-Santana, Óscar
Halkola, Anni S.
Wang, Wenyu
Mall, Raghvendra
Xiao, Xu
Kaufman, Jacob
Fu, Jingxin
Pfeil, Jacob
Banerjee, Jineta
Chung, Verena
Chang, Han
Chasalow, Scott D.
Lin, Hung Ying
Chai, Rongrong
Yu, Thomas
Finotello, Francesca
Mirtti, Tuomas
Mäyränpää, Mikko I.
Bao, Jie
Verschuren, Emmy W.
Ahmed, Eiman I.
Ceccarelli, Michele
Miller, Lance D.
Monaco, Gianni
Hendrickx, Wouter R. L.
Sherif, Shimaa
Yang, Lin
Tang, Ming
Gu, Shengqing Stan
Zhang, Wubing
Zhang, Yi
Zeng, Zexian
Das Sahu, Avinash
Liu, Yang
Yang, Wenxian
Bedognetti, Davide
Tang, Jing
Eduati, Federica
Laajala, Teemu D.
Geese, William J.
Guinney, Justin
Szustakowski, Joseph D.
Vincent, Benjamin G.
Carbone, David P. https://orcid.org/0000-0003-3002-1921
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02041533 at ClinicalTrials.govnct02477826 at ClinicalTrials.govDocuments that mention this clinical trial
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer
https://doi.org/10.1186/s12967-023-04705-3
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer
https://doi.org/10.1016/j.lungcan.2015.02.007
Documents that mention this clinical trial
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer
https://doi.org/10.1186/s12967-023-04705-3
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
https://doi.org/10.1200/jco.22.01503
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
- License Information
-
More Information
Article History
Received: 24 October 2023
Accepted: 5 November 2023
First Online: 21 February 2024
Declarations
:
: Not applicable.
: Not applicable.
: MM, HC, and HYL are employees of Bristol Myers Squibb. MIM has received lecture and/or advisory board fees from Boehringer Ingelheim, Bristol Myers Squibb, MSD, Takeda, Bayer, Amgen, Roche, and Aiforia Technologies Oy. WY is a shareholder of Aginome Scientific. JG is an employee of Tempus Labs. SSG is the recipient of a fellowship from the Sara Elizabeth O’Brien Trust. JS, SC, and WJG are employees and shareholders of Bristol Myers Squibb. BGV received consulting fees from GeneCentric Therapeutics. DPC has received advisory board fees, consulting fees, presentation fees, or consulting fees from Regeneron, Novartis, AbbVie, AstraZeneca, Bristol Myers Squibb, Roche, Arcus Biosciences, Mirati, Iovance Biotherapeutics, Pfizer, Onc Live, InThought, Glaxo-Smith Kline, Intellisphere, Sanofi, Merck KGgA, Merck/EMD Serono, Johnson & Johnson, Jazz, Janssen, Curio Science, PDD development, G1 Therapeutics, OncoHost, Eisai, Flame Biosciences, Novocure, Merck, Daiichi Sankyo, and Boehringer Ingelheim. Other authors declare that they do not have competing interests.
